Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PLSE |
---|---|---|
09:32 ET | 1808 | 10.77 |
09:36 ET | 500 | 10.95 |
09:57 ET | 100 | 10.91 |
09:59 ET | 6065 | 10.95 |
10:01 ET | 100 | 10.97 |
10:03 ET | 100 | 10.97 |
10:06 ET | 200 | 10.97 |
10:12 ET | 200 | 10.885 |
10:17 ET | 100 | 10.8 |
10:24 ET | 100 | 10.8 |
10:46 ET | 500 | 10.975 |
10:48 ET | 600 | 11.09 |
10:51 ET | 500 | 11.09 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Pulse Biosciences Inc | 598.1M | -13.6x | --- |
Nano-X Imaging Ltd | 413.2M | -6.5x | --- |
Atlantic International Corp | 291.9M | -0.4x | --- |
Orchestra Biomed Holdings Inc | 254.8M | -5.0x | --- |
Cibus Inc | 236.0M | -0.5x | --- |
MaxCyte Inc | 400.4M | -10.9x | --- |
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $598.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.76 |
EPS | $-0.82 |
Book Value | $0.80 |
P/E Ratio | -13.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.